Teva Opened a new sterile plant in Gödöllő Hungary

Teva Opened a new sterile plant in Gödöllő Hungary

​"This plant is the symbol of the harmony between the most up-to-date technology and the people, the creativity and hard work of our human capital"
The opening ceremony was held on Oct 2nd, in the presence of Viktor Orbán, Prime Minister of Hungary,  Jeremy Levin, Teva's President and CEO and Mihály Kaszás, CEO of Teva Pharmaceutical Works Hungary Ltd.

The opening of the new sterile plant means further strengthening of Teva's role in the Hungarian and international drug production. Due to the 110 million USD investment the new plant is one of the biggest and advanced manufacturing sites in the world, with annual production capacity of 160-200 million units of injection products in 6 production lines. With the 15,000 square meters production area and modular building, the new plant is not only one of the biggest sterile pharmaceutical plants but also one of the most flexible ones in the world. Thanks to the huge production potential and flexibility, the new plant can supply patients in more than 70 countries, mainly in the U.S., Europe and Far East.

In his opening speech, Jeremy Levin highlighted Teva's commitment to the highest quality drug production, and emphasized that the company has every confidence in the skill and dedication of Teva's Hungarian employees.

Mihály Kaszás said: "We are very proud of the investment, but even more proud of our employees who dreamt of this plant, who planned it, built it, equipped it, and also who will work in it. This plant is the symbol of the harmony between the most up-to-date technology and the people, the creativity and hard work of our human capital".

Teva has been operating in Hungary since 1993 and employs more than 3,500 people.
 

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.